Author: Lynne Taylor

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on proposed changes to its fee structure, which include increasing its medicines regulation fees by 2.8%.

Driven by an expanding patient population and the launches of a number of premium-priced branded treatments, the Russian market for drugs to treat prostate cancer is set to grow by around 6% each year to 2016, according to new forecasts.

Prescription drug treatment regimens for conditions that are a normal part of ageing are now costing the US more than many serious and potentially life-threatening conditions, new research shows.

Australia’s pharmaceutical industry has welcomed the government’s new White Paper, entitled Australia in the Asian Century, which forecasts that, by the end of this decade, Asia will overtake the economic output of Europe and North America combined to become the world’s largest economic power.

The European Parliament has finally approved the 2010 accounts of the European Medicines Agency (EMA).